J. Kalsi

A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction

R. Rees, S. Cellek, J. Kalsi, 2002, Expert opinion on investigational drugs.

A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats

D. Madge, D. Ralph, S. Cellek, 2004, International Journal of Impotence Research.

The effect of soluble guanylate cyclase activators and a nitric oxide releasing PDE 5 inhibitor on cavernosal and anococcygeal smooth muscle function in conditions of nitric oxide deficiency

J. Kalsi, 2011 .

ORIGINAL RESEARCH—BASIC SCIENCE: A Nitric Oxide‐Releasing PDE5 Inhibitor Relaxes Human Corpus Cavernosum in the Absence of Endogenous Nitric Oxide

S. Minhas, D. Ralph, P. Thomas, 2005 .

NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide

D. Ralph, S. Cellek, J. Kalsi, 2004, International Journal of Impotence Research.

BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro.

S. Moncada, A. Hobbs, D. Ralph, 2003, The Journal of urology.